Navigation Links
Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses

NEW YORK, Oct. 5 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses

Although the history of the biotechnology industry dates back to the late 19th century, It was only much later that biological organisms began to be modified for applications in agriculture, industrial production and medicine. The medical application of biotechnology began in earnest in the 1970s, growth has been strong as novel new medicines have been approved for conditions not previously treatable with conventional pharmaceuticals. Because they are biologically-derived but used for similar purposes as pharmaceutical products, these medications are also referred to as "biopharmaceuticals".

Biopharmaceuticals can be defined as therapeutics manufactured by biotechnology methods from biological sources, usually involving live organisms or their active components (bioprocessing, or directly involving surrogates, e.g., protein/gene sequences).

For the purpose of this report, biopharmaceuticals include the following broad therapeutic classes which can be further divided into other sub-classes:

Monoclonal antibodies;

Therapeutic proteins (inclusive of Insulin and analogs, erythropoietins, interferon alpha, interferon beta, blood coagulation factors, human growth hormone, enzymes, follicle stimulating hormone)

Vaccines (inclusive of vaccines manufactured only by recombinant technology)

Monoclonal antibodies were the largest sub-category, accounting for approximately half of the global biotechnology market in 2009. Hormones such as insulin & analogs, human growth hormone, and follicle stimulating hormone were the second largest sub-category. Growth factors, including erythropoietin and granulocyte colony stimulating factors were the third largest sub-category. Interferons, comprising of interferons alpha and beta were the fourth largest sub-category. The fifth in order were coagulation factors such as blood factors and coagulants. The last two sub-categories were of therapeutic enzymes and recombinant vaccines.

Key Features

  •  Overview of the global biotech industry
  •  Impact of the US healthcare reform on the biotech industry
  •  Market dynamics and performance of key sub-categories in 2009
  •  Detailed profiles of the top 10 global biotech players
  •  Strategic growth analyses and SWOT analyses of the top 10 global biotechnology players
  •  Short profiles of other leading players

  • Key Benefits

  •  Understand the dynamics of the global biotech market.
  •  Develop insights into leading sub-categories of the global biotech market, including monoclonal antibodies, hormones, growth factors, interferons, enzymes and vaccines.
  •  Examine the competitive landscape of the global biotech industry.
  •  Analyze individual SWOT analyses of key players in the global biotech industry.
  •  Gauge the sales performance and growth strategies of leading companies in global biotech market.

  • Highlights of the report

    Roche was the leading biotechnology company in the world generating $33bn in sales in 2009, at a Y-o-Y growth of 8.2% and a market share of 35.4%.

    The global biotechnology market generated $94.7bn in 2009 sales, demonstrating a Y-o-Y growth of 10.7%. The period from 2005 to 2009 was a lucrative period for the biotechnology market as it increased at a CAGR of 12.4%.

    Neulasta, Enbrel and Epogen represented Amgen's top three brands in 2009. The top 10 brands in the company's portfolio accounted for 88.8% of its total sales in 2009.

    Key questions answered by this report

  •  What are the key trends in the global biotech industry?
  •  Which were the leading players in the global biotech market?
  •  Which companies will drive the future of the global biotech market?
  •  What are the key strengths, weaknesses, threats, and opportunities for the leading global biotech players?
  •  How was the sales performance of leading players in the global biotech market post recent economic downturn?
  •  Which companies have the most promising pipeline products in the biotech industry?
  •  What are the growth strategies being implemented by leading biotech companies such as Roche, Amgen, Gilead, UCB and Biogen?

  • Table of ContentsAbout the author 2

    Disclaimer 2

    Executive summary 14

    Industry overview 14

    Roche 15

    Amgen 15

    Gilead Sciences 16

    UCB 16

    Biogen Idec 17

    Genzyme 17

    Cephalon 18

    CSL 19

    Celgene 19

    Amylin 20

    Chapter 1 Scope & methodology 21

    Scope 21

    Methodology 21

    Chapter 2 Industry Overview 22

    Summary 22

    Definition of biopharmaceuticals 23

    Key industry trends 24

    Evolution of the pharmaceutical-biotechnology relationship 24

    Impact on the US Healthcare reform on the biotech industry 25

    Rising costs for biotechnology companies 25

    Creation of a biosimilar legislation pathway 25

    Therapeutic tax credit legislation to benefit mid to small biotechnology companies 26

    IPO activity is expected to increase 26

    Increasing emphasis on comparative effectiveness studies 26

    Challenges facing biotech drug development 27

    Complicated disease targets 28

    Escalating costs 28

    Market dynamics 29

    Competitive landscape 32

    Chapter 3 Roche 34

    Summary 34

    Company overview 35

    Sales performance analysis 35

    Sales by drug class 36

    Marketed products 37

    Key brands analysis 38

    Avastin (bevacizumab) 38

    MabThera/Rituxan (rituximab) 40

    Herceptin (trastuzumab) 41

    R&D pipeline analysis 42

    Profiles of key late-stage pipeline products 43

    Oncology 43

    Autoimmune and inflammatory disorders 44

    Metabolic disorders 46

    Growth Strategies 47

    Expertise in mAb development and commercialization to allow continued domination 47

    Line-extension studies on leading oncology products are expected to further expand Roche's market


    Increasing focus on emerging markets in the Asia pacific region 49

    Other products to contribute strongly to near-term growth 49

    SWOT Analysis 50

    Chapter 4 Amgen 51

    Company overview 52

    Sales performance analysis 52

    Sales by therapeutic class 53

    Marketed products 54

    Key brands analysis 55

    Neulasta (pegfilgrastim)/ Neupogen(filgrastim) 55

    Enbrel (etanercept) 56

    Epogen (erythropoietin Alfa) 56

    Aranesp (darbepoetin alfa) 56

    R&D pipeline analysis 57

    Growth strategies 58

    Expanding the range of indications for denosumab 58

    Lifecycle management strategies on various product lines 58

    Strategic acquisitions and licensing partnerships 59

    SWOT analysis 62

    Chapter 5 Gilead Sciences 63

    Summary 63

    Company Overview 64

    Sales performance analysis 64

    Sales by therapeutic class 65

    Regional sales analysis 66

    Marketed products 67

    Key brands analysis 68

    Atripla (tenofovir/emtricitabine/efavirenz) 68

    Truvada (tenofovir/emtricitabine) 69

    Viread (tenofovir disoproxil fumarate) 70

    Ranexa (ranolazine) 71

    R&D pipeline analysis 71

    Profiles of key pipeline products 73

    Infectious diseases 73

    Growth strategies 76

    Continued leadership position in the HIV/AIDS market through line-extensions and robust pipeline 76

    Therapeutic area diversification is likely to drive the next wave of growth 76

    SWOT analysis 77

    Chapter 6 UCB 78

    Summary 78

    Company overview 79

    Sales performance analysis 79

    Sales by therapeutic class 80

    Regional sales analysis 81

    Marketed products 82

    Key brands analysis 83

    Keppra (levetiracetam) 83

    Neupro (rotigotine) 84

    Cimzia (certolizumab pegol) 84

    R&D pipeline analysis 85

    Profiles of key pipeline products 87

    CNS disorders 87

    Immunology 88

    Growth Strategies 89

    Transformation into a pure-play biopharmaceutical company to aid long-term growth 89

    The SHAPE program is expected to position UCB as a focused specialty player 90

    Strategic alliances to play a key role in UCB's future successes 90

    SWOT analysis 92

    Chapter 7 Biogen Idec 93

    Summary 93

    Company overview 94

    Sales performance analysis 94

    Sales by therapeutic class 95

    Regional sales analysis 96

    Marketed products 97

    Key Brands Analysis 98

    Avonex (interferon beta-1a) 98

    Tysabri (natalizumab) 99

    R&D pipeline analysis 100

    Profiles of key pipeline products 101

    Neurology 101

    Cardiology 103

    Growth Strategies 104

    Franchise extensions and new product development to allow Biogen Idec to retain strong control of

    the MS market 104

    Increasing focus on monoclonal antibodies (mAbs) to catalyze the next wave of growth 105

    SWOT analysis 106

    Chapter 8 Genzyme 107

    Summary 107

    Company Overview 108

    Sales performance analysis 108

    Sales by therapeutic class 109

    Regional sales analysis 110

    Marketed products 111

    Key brands analysis 112

    Renagel/Renvela (sevelamer) 112

    Cerezyme (imiglucerase) 113

    Fabrazyme (agalsidase beta) 114

    Myozyme (alglucosidase alpha) 115

    R&D pipeline analysis 116

    Profiles of key pipeline products 117

    Oncology/hematology 117

    Cardiometabolic diseases 118

    Genetic diseases 120

    Growth strategies 121

    Continued focus on rare diseases to aid market expansion 121

    Divestment of genetics and diagnostics businesses could create greater value 122

    Diversification of product offering to catalyze the next wave of growth 122

    SWOT analysis 123

    Chapter 9 Cephalon 124

    Summary 124

    Company overview 125

    Sales performance analysis 125

    Sales by therapeutic class 126

    Regional sales analysis 127

    Marketed products 128

    Key brands analysis 129

    Provigil (modafinil) 129

    Nuvigil (armodafinil) 130

    Treanda (bendamustine) 130

    R&D pipeline analysis 132

    Profiles of key pipeline products 133

    Inflammatory diseases 133

    Growth Strategies 135

    Lifecycle management of key brands to build successful franchises that contribute to long-term

    growth 135

    Partnerships and collaborations to allow therapeutic area diversification 135

    SWOT analysis 136

    Chapter 10 CSL 137

    Summary 137

    Company overview 138

    Sales performance analysis 139

    Sales by therapeutic class 139

    Regional sales analysis 140

    Marketed products 141

    Key brands analysis 142

    Carimune (immunoglobulin) 142

    Privigen (immunoglobulin) 142

    R&D pipeline analysis 143

    Profiles of key pipeline products (recently commercialized/under development) 144

    Hizentra 144

    Berinert 144

    Growth Strategies 145

    New product development to drive future growth 145

    Strategic collaborations to contribute to long-term growth potential 146

    SWOT analysis 147

    Chapter 11 Celgene 148

    Summary 148

    Company overview 149

    Sales performance analysis 149

    Sales by therapeutic class 150

    Regional sales analysis 151

    Marketed products 152

    Key brands analysis 153

    Revlimid (lenalidomidine) 153

    Vidaza (azacitidine) 154

    R&D pipeline analysis 155

    Profiles of key pipeline products 156

    Hematology/oncology 156

    Inflammation and Immunology 158

    Growth Strategies 159

    Leveraging thalidomide expertise to continue its dominance of the hematologic malignancies market


    Revlimid line-extension and geographic market expansion to drive the next wave of growth 160

    SWOT analysis 161

    Chapter 12 Amylin 162

    Summary 162

    Company overview 163

    Sales performance analysis 163

    Sales by therapeutic class 164

    Regional sales analysis 164

    Marketed products 165

    Key brands analysis 165

    Byetta (exenatide) 165

    Symlin (pramlintide) 167

    R&D pipeline analysis 168

    Profiles of key pipeline products 169

    Diabetes 169

    Obesity 170

    Growth strategies 171

    Amylin's partnership with Takeda to enhance its marketing reach and increase pipeline potential


    Bydureon and exenatide line-extensions to contribute to future growth 172

    SWOT analysis 173

    Chapter 13 Other major players 174

    Actelion 174

    Company overview 174

    Sales performance analysis 174

    Talecris Biotherapeutics 174

    Company overview 174

    Sales performance analysis 174

    Cubist 175

    Company overview 175

    Sales performance analysis 175

    Elan 175

    Company overview 175

    Sales performance analysis 175

    Abraxis BioScience 176

    Company overview 176

    Sales performance analysis 176

    Appendix 177

    Glossary/Abbreviations 177

    Table of figuresFigure 1: The global biotechnology market size, 2005-09 29

    Figure 2: Competitive dynamics of the global top 10 biotech market, 2009 33

    Figure 3: Roche's SWOT analysis 50

    Figure 4: R&D pipeline by therapeutic area focus and development stage, 2010 57

    Figure 5: Amgen's SWOT analysis 62

    Figure 6: Gilead's R&D pipeline by therapeutic area focus and development stage, 2010 72

    Figure 7: Gilead's SWOT analysis 77

    Figure 8: UCB's R&D pipeline by therapeutic focus and development stage, 2010 86

    Figure 9: UCB's SWOT analysis 92

    Figure 10: Biogen Idec's pipeline by R&D focus and development stage, 2010 100

    Figure 11: Biogen Idec's SWOT analysis 106

    Figure 12: Genzyme's R&D pipeline by therapeutic area focus and development stage, 2010 116

    Figure 13: Genzyme's SWOT analysis 123

    Figure 14: Cephalon's R&D pipeline by therapeutic area focus and development stage, 2010132

    Figure 15: Cephalon's SWOT analysis 136

    Figure 16: CSL's SWOT analysis 147

    Figure 17: Celgene's R&D pipeline by therapeutic area focus and development stage, 2010 155

    Figure 18: Celgene's SWOT analysis 161

    Figure 19: Amylin's pipeline by therapeutic area focus and development stage, 2010 168

    Figure 20: Amylin's SWOT analysis 173

    Table of tables

    Table 1: The global biotechnology market by therapeutic class, 2009 30

    Table 2: Top 10 players in the global biotech market, 2009 32

    Table 3: Roche's sales by leading drug class, 2009 36

    Table 4: Leading brands in Roche's product portfolio, 2009 37

    Table 5: Roche's R&D pipeline by therapeutic area focus and phase of development, 2010 42

    Table 6: Roche's key late-stage product pipeline, 2010 47

    Table 7: Amgen's sales by leading therapeutic class, 2009 53

    Table 8: Leading brands in Amgen's marketed product portfolio, 2009 54

    Table 9: Amgen's key late-stage R&D pipeline, 2010 61

    Table 10: Gilead's sales by leading drug class, 2009 65

    Table 11: Gilead's sales by region, 2009 66

    Table 12: Leading brands in Gilead's product portfolio, 2009 67

    Table 13: UCB's sales by leading therapeutic class, 2009 80

    Table 14: UCB's sales by region, 2009 81

    Table 15: Leading brands in UCB's marketed portfolio, 2009 82

    Table 16: Biogen Idec's sales by therapeutic class, 2009 95

    Table 17: Biogen Idec's sales by region, 2009 96

    Table 18: Leading brands in Biogen Idec's portfolio, 2009 97

    Table 19: Biogen Idec's key late-stage pipeline, 2010 104

    Table 20: Genzyme's sales by leading therapeutic class, 2009 109

    Table 21: Genzyme's sales by region, 2009 110

    Table 22: Leading brands in Genzyme's marketed product portfolio, 2009 111

    Table 23: Genzyme's key late-stage pipeline, 2010 121

    Table 24: Cephalon's sales by leading therapeutic class, 2009 126

    Table 25: Cephalon's sales by region, 2009 127

    Table 26: Leading brands in Cephalon's marketed product portfolio, 2009 128

    Table 27: Cephalon's key late-stage pipeline, 2010 134

    Table 28: CSL's sales by leading therapeutic class, 2009 139

    Table 29: CSL's sales by region, 2009 140

    Table 30: Leading brands in CSL's marketed product portfolio, 2009 141

    Table 31: CSL's pipeline, 2010 145

    Table 32: Celgene's sales by leading therapeutic class, 2009 150

    Table 33: Celgene's sales by region, 2009 151

    Table 34: Leading brands in Celgene's marketed product portfolio, 2009 152

    Table 35: Celgene's key late-stage pipeline, 2010 159

    Table 36: Amylin's sales by leading drug classes, 2009 164

    Table 37: Amylin's sales by region, 2009 164

    Table 38: Leading products in Amylin's marketed product portfolio, 2009 165

    To order this report:Biotechnology Industry: The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses

    Biotechnology Business News

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds US Forensic Technologies and Services Industry
    2. Reportlinker Adds Global Synthetic Biology Industry
    3. Reportlinker Adds Global Soft Tissue Allografts Industry
    4. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
    5. Reportlinker Adds Shire plc: PharmaVitae Profile
    6. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
    7. Reportlinker Adds Proteomics - Technologies, Markets and Companies
    8. Reportlinker Adds Biotechnology Pharmaceutical Market in US -2013
    9. Reportlinker Adds US Vaccines Market
    10. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
    11. Reportlinker Adds Womens Infertility - Pipeline Assessment and Market Forecasts to 2017
    Post Your Comments:
    (Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
    (Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
    (Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
    (Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
    Breaking Biology Technology:
    (Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
    (Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
    (Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
    Breaking Biology News(10 mins):